Cocrystal Pharma, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Cocrystal Pharma, Inc. (COCP), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are COCP insiders buying or selling?
In the last 12 months, Cocrystal Pharma, Inc. insiders reported 9 open-market purchases ($300.2K) and 0 sales ($0) — net buying of $300.2K. Since October 2019, Trabud has recorded 13 Form 4 filings for COCP: 12 buys ($2.4M) and 1 sells ($1.7M).
Source: SEC EDGAR Form 4
What stands out
- The largest open-market purchase in the last 12 months was $70.6K by Phillip Frost MD ET AL (Director, 10% Owner) on Aug 5, 2026. SEC ↗
- The most recent open-market purchase was reported on Aug 6, 2026 (2 months ago).
Key Statistics (October 2019 – Aug 6, 2026)
Total Form 4 filings
13
SEC EDGAR
Insider filers
3
Insider buys (12)
$2.4M
Insider sells (1)
$1.7M
Insider sentiment
Net buyingNet insider flow of $664.1K in net buying since October 2019, and $300.2K in net buying over the last 12 months. 2 insider buys in the last 90 days.
Recent COCP insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 10.0K | $0.98 | $9.8K | SEC ↗ |
| Aug 5, 2026 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 75.0K | $0.94 | $70.6K | SEC ↗ |
| Feb 25, 2026 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 20.0K | $1.00 | $20.0K | SEC ↗ |
| Feb 9, 2026 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 50.0K | $0.95 | $47.3K | SEC ↗ |
| Jan 2, 2026 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 50.0K | $0.95 | $47.3K | SEC ↗ |
| Dec 31, 2025 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 20.0K | $0.97 | $19.3K | SEC ↗ |
| Dec 29, 2025 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 65.0K | $0.97 | $63.2K | SEC ↗ |
| Nov 28, 2025 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 4.0K | $0.99 | $4.0K | SEC ↗ |
| Nov 26, 2025 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 20.0K | $0.94 | $18.8K | SEC ↗ |
| Apr 6, 2023 | Phillip Frost MD ET AL | Director, 10% Owner | Purchase | 1.0M | $1.97 | $2.0M | SEC ↗ |
| Aug 23, 2021 | Richard C Pfenniger JR | Director | Purchase | 40.0K | $1.03 | $41.1K | SEC ↗ |
| May 6, 2021 | Schinazi Raymond F | 10% Owner | Sale | 575.0K | $2.95 | $1.7M | SEC ↗ |
| Oct 29, 2019 | Schinazi Raymond F | 10% Owner | Purchase | 16.9K | $1.12 | $19.0K | SEC ↗ |
Showing the 13 most recent of 13 Form 4 filings for Cocrystal Pharma, Inc..
Most active COCP insiders
- Phillip Frost MD ET AL10 filings
- Schinazi Raymond F2 filings
- Richard C Pfenniger JR1 filing
Ask anything about COCP insider activity
Use Trabud's AI agent to query Cocrystal Pharma, Inc.'s Form 4 history in plain English — "Show me COCP CEO purchases this year" or compare it against any other ticker.
Open the AI agentCOCP insider trading FAQ
Are Cocrystal Pharma, Inc. insiders buying or selling?
In the last 12 months, Cocrystal Pharma, Inc. insiders reported 9 open-market purchases ($300.2K) and 0 sales ($0) — net buying of $300.2K. Since October 2019, Trabud has recorded 13 Form 4 filings for COCP: 12 buys ($2.4M) and 1 sells ($1.7M). Over the full record that is net buying of $664.1K.
How many insiders trade COCP stock?
3 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Cocrystal Pharma, Inc.. The most recent filing was accepted on Aug 6, 2026.
Where does Trabud get COCP insider trading data?
All COCP insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.